Clinical trial · Observational
Screening of Hereditary Upper Gastrointestinal Cancer in China
NCT03130621CI-TRIAL-00038907unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Through exploring the specific genetic mutations in the upper gastrointestinal tract tumors with a family history and specific clinical pathological types，we establish a complete family and follow-up system，in order to improve the screening criteria of Chinese hereditary upper gastrointestinal tumors and carry on primary prevention of disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Improve the Screening Criteria of Chinese Hereditary Upper Gastrointestinal Tumors | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gene detection | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Adenocarcinoma of upper digestive tract
- description
- Early-onset carcinomas ; Family History of Malignancy; Special pathological type; MSI or dMMR; Multiple primary malignant tumors;
- interventionNames
- Diagnostic Test: Gene detection
- label
- Esophageal squamous cell carcinoma
- description
- Family History of Malignancy; Multiple primary malignant tumors; MSI or dMMR;
- interventionNames
- Diagnostic Test: Gene detection
Primary outcomes (1)
- measure
- Pedigree analysis
- timeFrame
- In the first phase of the project, we plan to detect 40-50 families in one year. And in the second phase，we will increase the number of predigree to 200. We hope to finish the phase before 2022.3
- description
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: Patients with gastric cancer, esophageal adenocarcinoma, or duodenal adenocarcinoma meet one of the following criteria: 1. age≤30; 2. age≤35，gastric cancer with special pathological types; 3. age≤50，≥one first-degree relative of a malignant tumor; 4. ≥ two first-degree／second-degree relatives of a malignant tumor，and ≥one first-degree relative; 5. have ≥two types of malignancies，and age ≤50 at the first time of diagnosis; 6. MSI or dMMR of tissue specimen; Patients with esophageal squamous cell carcinomas meet one of the following criteria: 1. ≥ two first-degree／second-degree relatives of a malignant tumor，and ≥one first-degree relative; 2. have ≥two types of malignancies，and age ≤50 at the first time of diagnosis; 3. MSI or dMMR of tissue specimen; Exclusion Criteria: * Patients do not meet one of the inclusion criteria;
References
Publications (0)
Data not yet available
No reference posted for this study.